Amneal Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net income (loss) | $127,933 | $(73,876) | $(48,722) |
| Less: Net income attributable to non-controlling interests | (55,876) | (43,010) | (35,271) |
| Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | 72,057 | (116,886) | (83,993) |
| Other comprehensive (loss) income: | |||
| Foreign currency translation adjustments arising during the period | (18,685) | (5,788) | (1,059) |
| Unrealized loss on cash flow hedge, net of tax of $0 | (22,423) | (1,168) | (48,497) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | 1,229 | (26,205) | (3,366) |
| Other, net of tax of $0 | (5,340) | — | — |
| Less: Other comprehensive loss attributable to non-controlling interests | — | — | 9,875 |
| Other comprehensive loss attributable to Amneal Pharmaceuticals, Inc. | (45,219) | (33,161) | (43,047) |
| Comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. | $26,838 | $(150,047) | $(127,040) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.